Skip to content
Calculator
Evidence: MediumPeptideIn Clinical TrialsCXCR4 antagonist peptideInvestigational · phase 3 stoppedBreast cancer

Balixafortide

A CXCR4 blocker tested for stem cell mobilisation and breast cancer

Balixafortide is an investigational peptide that blocks the CXCR4 receptor. In healthy volunteers it released blood stem cells from the bone marrow, and with the chemotherapy drug eribulin it shrank tumours in 30% of women with metastatic breast cancer in a phase 1 trial. The phase 3 trial was halted early after failing its primary endpoint.

No dosing data yet Details ↓

Overview

What is it?

CXCR4 holds blood stem cells in the bone marrow and helps tumour cells survive and spread. Blocking it releases stem cells into the blood, which is how the approved peptide motixafortide is used before stem cell collection. In healthy volunteers, balixafortide mobilised stem cells at every dose, reaching about 38 CD34+ cells/µL at the higher doses, and was rated more favourably than G-CSF by participants. Compared with G-CSF, it raised B lymphocytes more and neutrophils and monocytes less, producing a mixed rise in white cells in the mid-20,000 per microlitre range.

In cancer it was combined with eribulin. A phase 1 trial in 56 women with HER2-negative metastatic breast cancer found no dose-limiting toxicities, and partial responses in 16 of 54 evaluable patients (30%). In mice with prostate cancer in bone, it enhanced docetaxel's effect on tumour burden.

The pivotal phase 3 trial, with 432 participants, was terminated: ClinicalTrials.gov records that it was halted early because it failed its primary endpoint. A further trial with nab-paclitaxel or eribulin was withdrawn by the funder, and a new phase 1 study with cosibelimab in pancreatic cancer is registered. It is not approved anywhere. A completed phase 2 trial of 120 participants also tested CXCR4 blockade with it for cell mobilisation and healing after acute myocardial infarction; no results paper was found.

Structured data

At a Glance

Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.

ClassAn investigational CXCR4 antagonist peptide that mobilises blood stem cells and was combined with eribulin for metastatic breast cancer; its phase 3 trial was halted early for failing its primary endpoint.
US statusIn Clinical Trials
Evidence levelMedium
Last reviewed2026-10-16

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Evidence

Published Research

Studies of balixafortide, from their PubMed abstracts.

Human2018

Phase 1 with eribulin in breast cancer

In 56 women with HER2-negative metastatic breast cancer, no dose-limiting toxicities were confirmed and the maximum tolerated dose was not reached; 16 of 54 evaluable patients (30%) had partial responses.

PMID: 29706375
Human2017

Stem cell mobilisation in healthy volunteers

Balixafortide mobilised stem and progenitor cells at all doses, reaching 38.2 CD34+ cells/µL at 1,500-2,500 µg/kg, was well tolerated and was rated favourably over G-CSF.

PMID: 28049490
Animal2023

Prostate cancer in bone, with docetaxel

In mice, adding balixafortide to docetaxel lowered tumour burden compared with docetaxel alone and reduced the area of bone lesions compared with vehicle.

PMID: 37244751
Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● No dose-limiting toxicities with eribulin in phase 1
● Mixed leukocytosis when used for mobilisation

Contraindications & Cautions

No label; it is investigational.

● Not approved for any use
Questions

Frequently Asked Questions

?What is balixafortide?

An investigational peptide that blocks the CXCR4 receptor, tested for releasing blood stem cells and, with eribulin, for metastatic breast cancer.

?Why was the phase 3 trial stopped?

ClinicalTrials.gov records that it was halted early because it failed to meet its primary endpoint.

?How does it relate to motixafortide?

Both are CXCR4-blocking peptides. Motixafortide is approved in the US for mobilising stem cells before collection in multiple myeloma; balixafortide is not approved.

?What did the phase 1 breast cancer trial show?

With eribulin, 30% of evaluable women had partial responses, no dose-limiting toxicities were confirmed, and the maximum tolerated dose was not reached.

?How does it compare with G-CSF for releasing stem cells?

In healthy volunteers it mobilised stem cells at every dose and was rated more favourably than G-CSF; it raised B lymphocytes more, and neutrophils and monocytes less, than G-CSF.

?Is balixafortide still being studied?

A phase 1 study combining it with the antibody cosibelimab in metastatic pancreatic cancer is registered on ClinicalTrials.gov as not yet recruiting, but no new breast cancer trials are active after the phase 3 termination.

?Can I buy balixafortide?

It is not approved anywhere, so anything sold under its name is an untested research chemical with no verified purity.

Bibliography

References

  1. [registry] ClinicalTrials.gov API v2, read October 3, 2026: NCT03786094 (phase 3, HER2-negative metastatic breast cancer, 432, terminated for failing primary endpoint), NCT01837095 (phase 1 with eribulin, 54, completed), NCT01905475 (phase 2, acute myocardial infarction, 120, completed), NCT04826016 (phase 1/2, withdrawn: funder decision).
  2. [clinical-trial] Pernas S, et al. "Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial." Lancet Oncol, 2018;19(6):812-824. PMID: 29706375.
  3. [clinical-trial] Karpova D, et al. "Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial." J Transl Med, 2017;15(1):2. PMID: 28049490.
  4. [pubmed] Robinson T, et al. "A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis." Prostate, 2023;83(13):1247-1254. PMID: 37244751.
  5. [pubmed] de Nigris F, et al. "CXCR4 inhibitors: tumor vasculature and therapeutic challenges." Recent Pat Anticancer Drug Discov, 2012;7(3):251-64. PMID: 22376154.
  6. [pubmed] Cortés J, et al. "CXCR4 antagonists for treatment of breast cancer." Oncotarget, 2018;9(71):33442-33443. PMID: 30323888.
  7. [pubmed] Wang Y, et al. "C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function." Circulation, 2019;139(15):1798-1812. PMID: 30696265.
  8. [pubmed] Huynh C, et al. "Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions." Pharmacol Res, 2020;161:105092. PMID: 32758634.
  9. [pubmed] Miao M, et al. "Clinical significance of chemokine receptor antagonists." Expert Opin Drug Metab Toxicol, 2020;16(1):11-30. PMID: 31903790.
  10. [pubmed] Martin M, et al. "At the Bedside: Profiling and treating patients with CXCR4-expressing cancers." J Leukoc Biol, 2021;109(5):953-967. PMID: 33089889.
  11. [pubmed] Singh DD, et al. "Targeting the CXCR4/CXCL12 Axis to Overcome Drug Resistance in Triple-Negative Breast Cancer." Cells, 2025;14(18). PMID: 41002447.
  12. [pubmed] Brenner L, et al. "Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis." Tomography, 2025;11(8). PMID: 40863873.
  13. [pubmed] Ciavattone NG, et al. "Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy." Sci Rep, 2025;15(1):5204. PMID: 39939722.
  14. [pubmed] Zhu S, et al. "Decoding thermal instability in peptide therapeutics links microheterogeneity to bioactivity loss." J Pharm Biomed Anal, 2026;281:117658. PMID: 42475801.
  15. [pubmed] Dhamecha KR, et al. "Theranostic applications of CXCR4-targeted imaging ligands in lymphoma: integrating diagnosis and precision therapy." Am J Nucl Med Mol Imaging, 2026;16(1):1-13. PMID: 41868688.
  16. [pubmed] Liao M, et al. "CXCR4: A Promising Novel Strategy for Lung Cancer Treatment." Biomolecules, 2026;16(2). PMID: 41750259.
  17. [pubmed] Jiang C, et al. "Dendritic Cells in the Immunoregulation of Myocardial Infarction: Mechanisms and Therapeutic Strategies." Cardiovasc Drugs Ther, 2026. PMID: 42720723.
  18. [pubmed] Rajendran A, et al. "C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions." Cancer Pathog Ther, 2026;4(3):208-218. PMID: 41732212.

Sources & Citations

Studies were read from their PubMed records; trial registrations from ClinicalTrials.gov, read October 3, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.

Last reviewed: 2026-10-16